Throughout this past year, our customers have faced formidable challenges, grappling with issues such as regulations, funding, and the ever-evolving technological landscape. Viedoc has felt the reverberations and, in response, tailored our support and offerings accordingly.
The unmistakable surge in technology, particularly artificial intelligence, caught our attention early on. Our initial assessment revealed promising efficiencies across all facets of the clinical trial life cycle. Successfully implementing artificial intelligence for our internal operations, we've embraced this technology with a dual purpose—to reduce manual work and mitigate risks.
Despite slowdowns in certain market segments, notably the early-phase market, Viedoc has consistently showcased its value in terms of time savings and risk mitigation. Consequently, we've outpaced market growth significantly, experiencing an all-time high in quotes sent out to customers.
Another source of satisfaction is the success of our investment in the US market, now our fastest-growing region. The steady influx of new US-based customers seeking to enhance their workflows and experience shorter setup times is a testament to our strategic direction.
Outstanding reviews on benchmarking sites like G2 this year reinforced our confidence in the path we're forging. Viedoc was announced as the top EDC solution for the Fall of 2023, as well as Winter Leader 2023, Spring Leader 2023, and Summer Leader 2023. Our consistent presence at the top of leaderboards, wholly based on user reviews, is a direct result of the trust we have earned from our users, and we are profoundly grateful for their continued support. Viedoc was also the recipient of six Excellence Awards 2023 from Global Data’s Clinical Trials Arena and Pharmaceutical Technology.
Internally, the pinnacle of our year was undoubtedly the company gathering in May, where Sweden graced us with its sunniest disposition. Against the backdrop of clear, blue skies, we engaged in teamwork, shared insights, and shared laughter, creating memories that will remain with us for years to come.
Staying with our team, Viedoc has increased the number of full-time employees globally by at a high pace, with key appointments in the US and our first employee in Australia.
Beyond numerous product enhancements, expanded development teams, and a strengthened support structure, we've also embarked on new ESG initiatives. Firstly, we now offer free licenses for clinical trials aligned with the United Nations' Sustainable Development Goals. Additionally, we provide carbon emission details for each study our customers undertake, demonstrating our commitment to doing good and fostering transparency.
A glimpse into 2024 reveals our unwavering commitment to further invest in product development and service delivery. In the US, we're bucking the trend by establishing a physical office, recognizing that while our product is exceptional, it's the Viedocers who truly make the difference. As the saying goes, culture eats strategy for breakfast. Building a robust culture is best achieved through personal connections, genuine care, and mutual support.
Happy holidays and thank you for another great year.
Mats Klaar,
CEO
"Viedoc makes building a study easy and fun. It doesn't require extensive coding knowledge; it's quick to get in and start working."